Evoke Pharma Inc (NAS:EVOK)

$ 4.3501 -0.0799 (-1.8%) Market Cap: 6.46 Mil Enterprise Value: 244,000.00 PE Ratio: 0 PB Ratio: 0.89 GF Score: 44/100

Q4 2023 Evoke Pharma Inc Earnings Call Transcript
Mar 14, 2024

$8.1 (+5.24%)

Earnings
Evoke Pharma Inc KOL Webinar on HRCU Data Transcript
Jun 22, 2023
Q4 2022 Evoke Pharma Inc Earnings Call Transcript
Mar 21, 2023

$37.2 (+6.53%)

Earnings
Q3 2022 Evoke Pharma Inc Earnings Call Transcript
Nov 09, 2022

$19.32

Earnings
Q2 2022 Evoke Pharma Inc Earnings Call Transcript
Aug 10, 2022

$37.32 (-0.96%)

Earnings
Q1 2022 Evoke Pharma Inc Earnings Call Transcript
May 10, 2022

$49.68 (-7.90%)

Earnings
Q3 2021 Evoke Pharma Inc Earnings Call Transcript
Nov 10, 2021

$174.24 (-6.92%)

Earnings
Q2 2021 Evoke Pharma Inc Earnings Call Transcript
Aug 12, 2021

$161.28 (-1.75%)

Earnings
Q1 2021 Evoke Pharma Inc Earnings Call Transcript
May 12, 2021

$218.88 (-2.56%)

Earnings
Evoke Pharma Inc Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis Transcript
Apr 01, 2021

Q4 2022 Evoke Pharma Inc Earnings Call Transcript

Mar 21, 2023 / 08:30PM GMT

Release Date Price: $37.2 (+6.53%)

Transcript 10-K8-K

Operator

Good afternoon, and welcome to the Evoke Pharma fourth quarter and full year 2022 earnings conference call. (Operator Instructions) Please be advised that today's call is being recorded. I will now turn the call over to Daniel Kontoh-Boateng. Thank you, and you may begin.

Daniel Kontoh;Boateng

Tiberend Strategic Advisors, Inc. - IR

Good afternoon and thank you for participating in Evoke Pharma's conference call today. With me today are David Gonyer, Chief Executive Officer; Chris Quesenberry, GIMOTI's Chief Commercial Officer from Eversana; and Matthew J. D'Onofrio, Evoke's Chief Business Officer.

By now you should have a copy of the press release we issued earlier. If not, it is available on the Investor Relations page of our website at evokepharma.com. We encourage everyone to read today's press release as well as Evoke's Annual Report on Form 10-K, which is now filed with the SEC. The company's Form 10-K and earnings release are also available on Evoke's website.

Please note that certain information discussed on the call

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.